Blueprint Medicines

Home/Tag: Blueprint Medicines

Blueprint & Deciphera Celebrate GIST Awareness Day 2020 – Galleries

Blueprint Medicines and Deciphera Pharmaceuticals celebrated GIST Awareness Day (GAD), July 13th, 2020, with Virtual Walks across the U.S. This year's GIST Awareness Day theme was #GISTHope.

By |2020-07-20T08:41:11-04:00July 17th, 2020|Advocacy, News, Photos|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

By |2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|

NCI Mentions LRG as Component in Development of Ayvakit

In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.

By |2020-02-07T14:23:48-05:00February 7th, 2020|D842V, Drug Treatment, News, Patient Registry|

Blueprint Medicines Announces Next Step for Avaprinitib

Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]

By |2019-08-07T13:24:21-04:00August 7th, 2019|Drug Treatment, News|

Global GIST Advocates Convene at LRG Headquarters

The Life Raft Group had the pleasure of hosting the global New Horizons GIST meeting this year in our Wayne, New Jersey office. This international meeting traditionally gathers global GIST advocates with the shared [...]

By |2019-09-24T11:24:53-04:00December 28th, 2017|Advocacy, Global, News, Newsletter|

La Jolla Provided a Beautiful Backdrop for Our Three-Day July Event

The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]

By |2019-08-01T10:07:21-04:00September 18th, 2017|Advocacy, Caregiver Support, Events, GDOL, GIST Education, News, Newsletter|

Update on Blueprint Medicines Clinical Trial for BLU-285

Recently a number of companies have begun to develop therapeutic options that target some of the rarer mutations in GIST. As there are currently no approved treatments specifically for these patients, this [...]

By |2019-07-03T10:45:21-04:00May 24th, 2016|Clinical Trials, News, Research|

Blueprint Medicines Presents Preclinical Data on BLU-285

Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in  treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]

By |2019-04-08T10:13:47-04:00April 24th, 2015|D842V, News, Research|
Go to Top